SEARCH

SEARCH BY CITATION

References

  • 1
    Balducci L, Extermann M. Cancer and aging: an evolving panorama. Hematol Oncol Clin North Am. 2000; 14: 1-16.
  • 2
    Kouroukis C, Browman G, Esmail R, et al. Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non Hodgkin lymphoma: a systematic review. Ann Intern Med. 2002; 136: 144-152.
  • 3
    Peters FPJ, Lalisang RI, Fickers MMF, et al. Treatment of elderly patients with intermediate and high grade non Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol. 2001; 80: 155-159.
  • 4
    Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adult. J Clin Oncol. 2005; 23: 4117-4126.
  • 5
    Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol. 2007; 25: 1916-1923.
  • 6
    Balducci L, Beghe C. The application of the principles of geriatrics to the management of the older person with cancer. Crit Rev Oncol Hematol. 2000; 35: 147-154.
  • 7
    Extermann M, Hurria A. Comprehensive Geriatric Assessment for older patients with cancer. J Clin Oncol. 2007; 25: 1824-1831.
  • 8
    Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged: the index of ADL-A standardized measure of biological and psychosocial function. JAMA. 1963; 185: 914-919.
  • 9
    Miller MD, Towers A. A Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Pittsburg, PA: University of Pittsburg; 1991.
  • 10
    The International Non Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329: 987-994.
  • 11
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med. 2002; 346: 235-242.
  • 12
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.
  • 13
    Karnofsky DA: Clinical evaluation of anticancer drugs: cancer chemotherapy. Gann Monogr. 1967; 2: 223-321.
  • 14
    Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-391.
  • 15
    Intragumtornchai T, Bunworasate U, Nakorn TN, et al. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non Hodgkin's lymphoma. Leuk Lymphoma. 2006; 47: 1306-1314.
  • 16
    Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003; 21: 1255-1262.